Huntington's disease: effect of memantine on FDG-PET brain metabolism?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  The Journal of Neuropsychiatry and Clinical Neurosciences

• Publication date

  2011-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/appi.neuropsych.23.2.206PMID 21677252
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thalamic metabolism and symptom onset in preclinical Huntington's disease.

  2007cited by this paper
• Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease.

  2007cited by this paper
• A pilot study of the clinical efficacy and safety of memantine for Huntington's disease.

  2007cited by this paper
• Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease.

  2006cited by this paper
• Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.

  2006cited by this paper
• Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease

  2005cited by this paper
• Biomarkers for neurodegenerative diseases

  2005cited by this paper
• The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.

  2004cited by this paper
• Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.

  2004cited by this paper
• Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.

  1996cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease.

  1992cited by this paper
• Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268

  1990cited by this paper
• Circulatory and Metabolic Correlates of Brain Function in Normal Humans

  1987cited by this paper

• Fountain of youth—Targeting autophagy in aging

  2023cites this paper
• Imaging in Huntington’s

  2021cites this paper
• Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington’s disease

  2019cites this paper
• Metal homeostasis disturbances in neurodegenerative disorders, with special emphasis on Creutzfeldt-Jakob disease - Potential pathogenetic mechanism and therapeutic implications.

  2019cites this paper
• New directions in therapeutics for Huntington disease.

  2018cites this paper
• Connectomic imaging reveals Huntington‐related pathological and pharmaceutical effects in a mouse model

  2018cites this paper
• Current status of PET imaging in Huntington’s disease

  2016cites this paper
• Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification

  2016cites this paper
• Development and evaluation of biomarkers in Huntington’s Disease: furthering our understanding of the disease and preparing for clinical trials

  2014cites this paper
• Longitudinal Neuroimaging Biomarkers in Huntington's Disease

  2013cites this paper
• Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development

  2011cites this paper